---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335010"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2026-08-05T20:02:14+00:00"
generated_at: "2026-08-05T20:03:14.318512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q2 2026 revenue $26.9M (+34% YoY); net loss improves 37% to $7.3M

## Summary
- Diagnostic testing revenue $25.4M (+42% YoY) on 20,900 test volumes (+38%).
- Gross margin 82% (up 200 bps); operating expenses +7% vs revenue +34% shows leverage.
- Net loss $7.3M (improved 37%); Adjusted EBITDA loss $3.2M (improved 56%).
- FY 2026 revenue guidance maintained at $108-114M (midpoint ~25% growth); gross margin ~80%.
- Cash $30.0M, up 17% from Q1 2026; includes $6.5M from ATM program.

## SEC filing metadata
- accession: 0001193125-26-335010
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2026-08-05T20:02:14+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/0001193125-26-335010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000119312526335010/bdsx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335010
- JSON: https://secwatch.observer/filing/0001193125-26-335010.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.